This jewellery stock stages major turnaround, rebounds over 400% in three years; what’s behind the rally?

FDA approves AbbVie’s Juvmo for Parkinson’s disease treatment

Investing.com · News 7m ago

Lantheus doses first patient in prostate cancer imaging trial

Investing.com · News 7m ago

ALX Oncology reports trial data for gastric cancer drug

Investing.com · News 7m ago

Tempus AI receives FDA clearance for heart valve AI tool

Investing.com · News 7m ago

NeOnc schedules FDA meeting on brain cancer drug trial

Investing.com · News 7m ago

Allarity expands lab capabilities to support drug research

Investing.com · News 7m ago

Cantor Fitzgerald reiterates Neutral rating on Rivian stock at $19

Investing.com · News 8m ago

Cantor Fitzgerald reiterates Lucid stock rating on Saudi plant progress

Investing.com · News 8m ago

Brookline initiates Revolution Medicines stock with buy rating

Investing.com · News 8m ago

Cantor Fitzgerald reiterates Tesla stock rating on trucking outlook

Investing.com · News 8m ago